SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a significant rebound following a period of intense short selling and recent earnings. Community members are actively discussing the potential for a short squeeze, citing high short interest and positive analyst ratings, and celebrating the stock's resilience amid market volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending as investors react to the company's announcement regarding the completion of its BlueBird 6 satellite and the planned launch schedule, generating excitement about upcoming milestones. The community is buzzing with bullish sentiment, anticipating new all-time highs and significant long-term growth potential. Some traders are closely monitoring short positions and expecting a potential squeeze.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending amid a broader crypto rally and strategic restructuring, particularly following the sale of its loyalty business and the appointment of a new board member. The community is actively discussing the potential for a short squeeze and the company's focus on digital assets, with some speculating about future partnerships and expansion. Recent corporate execution and strong year-over-year growth are also driving positive sentiment.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending as traders discuss its recent price surge and potential catalysts, including unusual call buying activity and overall strength in the digital asset sector. Community members are debating whether the stock will continue its upward momentum or face profit-taking, while also weighing the impact of potential interest rate cuts on the company's revenue model. Some traders are closely watching key technical levels and potential breakout points.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending due to significant call buying activity and a recent price surge, sparking bullish sentiment. The community is actively discussing potential price targets and the correlation with Bitcoin's movements, while also debating its valuation relative to peers like Robinhood. Some are drawing comparisons to past financial crises, adding a layer of caution to the enthusiasm.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses the implications of David Schwartz stepping down as CTO.  Bullish sentiment is fueled by discussions around institutional adoption, tokenization, and cross-border payment utility, with some speculating on significant price movement.  Despite positive news, XRP struggles to break the $3 mark, leading to frustration and debate about market manipulation and future potential.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending after announcing multiple AI partnerships with Nvidia, OpenAI, and Snowflake, sparking excitement about its leadership in agentic AI. The community is buzzing about a potential short squeeze, with some comparing PATH to competitors like $PLTR.  However, some concerns remain around the CEO's ongoing stock sales.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to community speculation around positive news, a potential short squeeze, and renewed confidence in the stock's long-term prospects. Community members are actively discussing resistance levels and potential buyout scenarios, with some highlighting the stock's undervaluation relative to its revenue. Some traders are awaiting news to confirm a sustainable uptrend.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors discuss its potential following Keybanc's Overweight rating and price target adjustment. Community members are focused on the company's key support level, potential for growth, and anticipation of a significant move upward. The stock's relationship to the broader building products sector and management's strategy are also being closely watched.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending amid discussions around Berkshire Hathaway's investment moves, with some questioning the wisdom of divesting its OxyChem unit. The community is debating whether the sale strengthens OXY's focus on oil and gas or if it sacrifices diversification and a reliable cash flow stream. Investors are also weighing the impact of debt reduction and potential share buybacks against concerns about exposure to volatile oil prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tesla, AeroVironment and Progress Software fall premarket; MSC Industrial rises

Investing.com -- U.S. stock futures slipped lower Tuesday, dropping back from record levels as investors digested the latest news on trade deals, the Trump administration’s tax bill as well as upcoming key economic data.

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1).Dyne said it will now use video hand opening time (vHOT) as the primary endpoint, which measures the change from baseline in middle finger myotonia at six months compared to placebo.&nbsp;The update follows a Type C meeting with the U.S. Food and Drug Administration, which agreed vHOT could serve as an intermediate clinical endpoint to support a future submission for accelerated approval.The revised protocol was submitted to the FDA earlier this month.&nbsp;Dyne plans to complete enrollment in the expansion cohort during the fourth quarter, with 60 participants randomized 3:1 to receive either DYNE-101 or placebo.The revised expansion cohort will consist of 60 participants, randomized 3:1 to receive DYNE-101 at 6.8 mg/kg every eight weeks or placebo.&nbsp;Secondary endpoints include measures of muscle strength, walking performance, splicing biomarkers, and patient-reported outcomes.&nbsp;Enrollment is expected to be completed in Q4 2025, with pivotal data expected in mid-2026.Data from the 12-month cohort of the MAD study showed sustained effects on all measures, including vHOT and strength testing, where patients improved by 20% from baseline.&nbsp;The company also reported a favorable safety profile, with no treatment-related serious adverse events in the 56 participants dosed to date.Dyne plans to initiate a confirmatory Phase 3 trial in early 2026.&nbsp;It also reiterated that its cash balance of $677.5 million as of March 31 will fund operations into Q4 2026.Stifel analyst Paul Matteis said the change “comes as a surprise” and “will raise questions,” though he maintained a ‘Buy’ rating on the stock, suggesting the move could offer a clearer approval route.&nbsp;Meanwhile, H.C. Wainwright called the change “encouraging,” noting that powering the trial to 60 participants could improve confidence in vHOT and help detect trends across secondary endpoints.Chardan Capital also reiterated a ‘Buy’ rating and said the FDA’s confirmation of an accelerated pathway “more than offsets” a potential six-month delay to a Biologics License Application (BLA).&nbsp;The firm described the pullback as an “attractive entry point,” with the stock down 41% year-to-date.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial

The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes. 

Equity

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.84	--	--	N/A
Q2 '25	-$0.94	-$0.97	-2.96%	MISSED
Q1 '25	-$0.85	-$1.05	-22.95%	MISSED
Q4 '24	-$0.91	-$0.88	3.38%	BEAT
Q3 '24	-$0.71	-$0.96	-34.84%	MISSED

DYN
Dyne Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest DYN News

DYN Dyne Therapeutics Inc